CAR-T– tag –
-
AI Transforms Hematopoietic Stem Cell Research: Digital Twins and Reinforcement Learning Applied from Disease Modeling to Industrial CAR-T Cell Manufacturing
Baishideng Publishing Group Global Overview Artificial Intelligence (AI) shows vast potential in hematopoietic stem cell (HSC) research and related malignancies, spanning from disease modeling to cell manufacturing. Notably, digital twin... -
Bristol Myers Squibb Terminates $380M CAR-T Manufacturing Partnership with Cellares Due to Production Failures for Breyanzi
PharmaLive USA Overview Bristol Myers Squibb (BMS) has ended its $380 million partnership with Cellares, citing Cellares' Cell Shuttle system's failure to meet commercial production requirements for BMS's CAR T-cell immunotherapy, Breyan... -
CRISPR Therapeutics Diversifies Pipeline into In Vivo Gene Editing and Off-the-Shelf CAR-T Cell Therapies, Leveraging Casgevy Commercialization Experience
Venture Atlas USA Overview CRISPR Therapeutics is strategically diversifying its pipeline, leveraging its commercialization experience with Casgevy, into in vivo gene editing programs (CTX310, CTX320, CTX340, CTX460) and allogeneic off-t... -
CRISPR/Cas9 Evolves into Multi-Tool: Expanding Applications from Leukemia Screening to CAR-T Cell Engineering and Epigenome Editing
NHSJS USA Overview CRISPR/Cas9 technology has significantly evolved, broadening its applications from screening leukemia mutations to enhancing CAR-T cells' cancer recognition and precisely controlling gene expression through epigenome e... -
Moffitt Cancer Center’s Dr. Yvonne Chen Proposes Novel Strategies to Overcome Tumor Microenvironment Barriers in Solid Tumors with Logic-Gated CAR T-Cells
Moffitt Cancer Center USA Overview Dr. Yvonne Chen of Moffitt Cancer Center has discussed new strategies to enhance CAR-T cell therapy for solid tumors, focusing on precise targeting with logic-gated CAR-T cells and reprogramming the tum... -
CRDWC 2026 Symposium to Address CAR-T Challenges in Solid Tumors: Focus on Design, Manufacturing, and Safety Strategies
CRDWC 2026 (Cancer Research and Development Conference 2026) Unknown Overview The 2026 Cancer Research and Development Conference will host a symposium dedicated to expanding CAR-T cell therapy from hematological malignancies to solid tu... -
Virica Biotech Announces CAR-T Lentivirus Manufacturing Innovations and AAV Production Optimization with FUJIFILM
Virica Biotech Canada Overview Virica Biotech has announced innovative advancements in lentiviral vector manufacturing for CAR-T therapies, highlighted by a May 19, 2026, poster presentation featuring high productivity and smarter purifi... -
Decentralizing CAR-T Manufacturing: Point-of-Care Production to Slash Turnaround Times and Expand Therapeutic Access
Frontiers in Immunology Switzerland Overview CAR-T cell therapy, reliant on centralized manufacturing, is resource-intensive, time-consuming, and vulnerable to logistical disruptions. Interest in decentralized or point-of-care (POC) manu... -
Off-the-Shelf CAR T Therapies Revolutionize Cancer Treatment: Simplifying Manufacturing with Healthy Donor Cells, Reducing Wait Times and Costs
Katie Couric Media USA Overview Next-generation allogeneic CAR T-cell therapy, or 'off-the-shelf CAR T,' utilizes healthy donor cells instead of patient-specific cells, enabling large-batch manufacturing and extended storage. This signif... -
In Vivo CAR-T Cell Therapy Demonstrates Clinical Proof-of-Concept with AI Acceleration: Enabling Direct In-Body Immune Cell Gene Editing Towards ‘Off-the-Shelf Biologics’
OncoDaily International Overview While autologous CAR-T cell therapy yields durable remissions in B-cell malignancies, its delivery model faces persistent challenges. In vivo CAR-T emerges as a radically different approach, delivering CA...
